OmniAb Inc
OABI
查看详细走势图
1.700USD
+0.050+3.03%
收盘 02/06, 16:00（美东）报价延迟15分钟
244.72M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.03%
5天
-6.59%
1月
-10.53%
6月
-9.57%
今年开始到现在
-8.11%
1年
-52.78%
查看详细走势图
TradingKey OmniAb Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
OmniAb Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名124/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价7.33。中期看，股价处于上升通道。近一个月，市场表现较差，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
OmniAb Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
OmniAb Inc亮点
亮点风险
OmniAb, Inc. licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets.
业绩增长期
公司处于发展阶段，最新年度总收入26.39M美元
利润高增长
公司净利润处于行业前列，最新年度总收入26.39M美元
估值高估
公司最新PE估值-2.89，处于3年历史高位
机构减仓
最新机构持股79.79M股，环比减少21.46%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值95.33K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.18
分析师目标
根据
7
位分析师
买入
评级
7.333
目标均价
+321.46%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
OmniAb Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
OmniAb Inc简介
OmniAb, Inc. licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets.
公司代码OABI
公司OmniAb Inc
CEOFoehr (Matthew William)
网址https://www.omniab.com/
相关品种
